TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04393493
Drug: Furosemide intravenous solution
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administrated as an 80 mg intravenous bolus every 24 hours in both arms and then as a continuous infusion dosed according to the experimental arm.
Study: NCT04393493
Drug: Chlortalidone
Normalized name: Chlortalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 50 mg pill administrated every 24 hours in group B
Study: NCT00778115
Drug: Loperamide HCl 2 mg and simethicone 125 mg tablets
Normalized name: Loperamide Hydrochloride and Simethicone Tablets
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04443036
Drug: Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * 125mg/m2 IV d1、8，Q3W~* until disease progression, lost follow-up visit, death , unacceptable toxicity
Study: NCT04443036
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 240 mg，IV d1，Q3W~* until disease progression, lost follow-up visit, death , unacceptable toxicity, Maximum treatment duration is 24 months
Study: NCT00376792
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02910466
Drug: rhPTH(1-84)
Normalized name: rhPTH(1-84)
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 25, 50, 75, and 100 microgram (mcg) of rhPTH(1-84) subcutaneous injection to the thigh via a multidose pen injector device once daily for 36 months. The dose will be individualized based on Albumin-corrected Serum Calcium (ACSC) and 24-hour calcium urinary excretion to achieve a serum calcium level in the lower half of the normal range.
Study: NCT02662530
Drug: Botulinum Toxin Type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined either by visual/clinical or by biomechanical analysis of dystonic movements for cervical dystonia therapy in neck and shoulder muscles every 12 weeks over 30 weeks. BoNT-A dose will range from 50-300 U.
Study: NCT02982642
Drug: 1612 capsule
Normalized name: Oral Capsule
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be assigned 1612 capsule,3 capsules per time(0.38g per capsule), 3 times per day.1612 capsule is a Chinse herbal medicine,which can tonification of spleen and kidney, mainly contains shudihuang(Rehmannia glutinosa),shanyao(Dioscorea opposita),shichangpu(Uncaria rhynchophylla)and so on,
Study: NCT04173403
Drug: Statins and/or Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lipid-lowering therapies
Study: NCT00102063
Drug: Aripiprazole tablet, 10 mg
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole tablet 10 mg po qd x 42 days
Study: NCT00102063
Drug: Aripiprazole tablet, 30 mg
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole tablet 30 mg po qd x 42 days
Study: NCT04300426
Drug: ACHIM as solute (10^9 intestinal microbes/ml)
Normalized name: PORK INTESTINE
DrugBank: Pork (DB10561)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culture of intesinal microbiota originally derived from a healthy subject are administered to a person with presumed dysbiotic intestinal symptoms with an objective to treat these symptoms.
Study: NCT03255096
Drug: RO6870810
Normalized name: BET INHIBITOR RO6870810
DrugBank: RO-6870810 (DB15151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO6870810 subcutaneously (SC) at dose of 0.30, 0.45, or 0.65 milligram per kilogram (mg/kg) on Days 1-14 of 21-day cycles.
Study: NCT03255096
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax tablets orally at dose of 400 mg once daily (QD) continuously for 21 days.
Study: NCT03255096
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab intravenously (IV) at dose of 375 mg/m\^2 weekly during the first 21-day cycle (C1) and on day 1 of each cycle thereafter.
Study: NCT03774459
Drug: High dose ANAVEX2-73
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active oral capsule
Study: NCT03774459
Drug: Mid dose ANAVEX2-73
Normalized name: ANAVEX2-73
DrugBank: Blarcamesine (DB05592)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active oral capsule
Study: NCT00588809
Drug: selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01038648
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100mg/day
Study: NCT00126425
Drug: 123I-mIBG (meta-iodobenzylguanidine)
Normalized name: mIBG
DrugBank: Iobenguane (DB06704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT02094625
Drug: N-Acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NAC will be administered intravenously over \~60 minutes starting 4 hours following completion of cisplatin chemotherapy.~Three dose levels have been pre-determined:~Dose Level 1: 225 mg/kg Dose Level 2: 300 mg/kg Dose Level 3: 450 mg/kg~Should Dose Level 3 exceed the MTD, the study will examine blood levels of NAC and if below the target blood level necessary for hearing protection, the study will de-escalate from Dose Level 3 to an intermediate Dose Level 2.5 and test a dose of 375 mg/kg.~As of August 2018: Dose escalation completed with MTD not reached. Dose level 3 (450mg/kg) selected for expansion with NAC.
Study: NCT01872403
Drug: nanoparticle albumin-bound paclitaxel/carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin vs. paclitaxel /carboplatin in stage Ⅱ B and IIIA squamous cell carcinoma of the lung:
Study: NCT01801410
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mcg every 2 hours for maximum of 12 doses
Study: NCT02425111
Drug: Vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab intravenous injection
Study: NCT03621696
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: -100 mg/m\^2 intravenous push bolus (IVPB)
Study: NCT04417361
Drug: Galcanezumab Prefilled Syringe
Normalized name: galcanezumab Prefilled Syringe
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Galcanezumab will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.
Study: NCT02341352
Drug: fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium fluoride 50mg/ml
Study: NCT01688089
Drug: Entacapone
Normalized name: Entacapone
DrugBank: Entacapone (DB00494)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00177216
Drug: Zolpidem
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The benzodiazepine receptor agonist (BzRA), zolpidem was given in an initial dose of 5 mg by mouth every night, 30 minutes prior to bedtime. The dose was increased to a maximum of 10 mg after the first week if there was no improvement in overall symptoms (CGI score of 4 or \>). The dose was decreased to 5 mg if side effects occurred.
Study: NCT00177216
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The antidepressant, escitalopram was initiated at 5 mg by mouth every night, 30 minutes prior to bedtime. If there were no side effects, the dose was increased every four days until the target dose of 20 mg (maximum dose) was reached by day 13. If significant side effects appeared, the highest tolerated dose was used.
Study: NCT01492205
Drug: insulin human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects were treated with human insulin administered either by using the NovoLet® pre-filled insulin system or the conventional vial and syringe method. Doctors and nurses must personally administer at least 10 insulin doses to each patient under their individual clinical supervision for assessment of the NovoLet® pre-filled insulin system
Study: NCT00965250
Drug: IMC-12
Normalized name: IMC-18F1
DrugBank: MC-1 (DB05315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg intravenously once every three weeks
Study: NCT03383146
Drug: Relamorelin
Normalized name: Relamorelin
DrugBank: Relamorelin (DB12678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relamorelin 10 μg injected subcutaneously twice daily.
Study: NCT00984737
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capillary glucose measurements of Group 2 and Group 3 will be performed during hospitalization and will be treated when they are over 180mg/dl.~Short acting oral anti-diabetic drugs will be given to patients who refuse insulin injection.
Study: NCT02838342
Drug: Interferon-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 months of treatment from the 4th cycle metronomic cyclophosphamide : subcutaneous injection, initial dose of 3 MIU three times a week. The dose may be adjusted as tolerated to achieve a T cell counts greater than 500 / mm3
Study: NCT00448721
Drug: Perifosine
Normalized name: Perifosine
DrugBank: Perifosine (DB06641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perifosine will be administered orally at 100mg PO daily with food.
Study: NCT01862536
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily use of study drug to treat pulmonary hypertension.
Study: NCT00639002
Drug: Ruxolitinib 25 mg
Normalized name: ruxolitinib 25 MG
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib was supplied as 5 and 25 mg tablets.
Study: NCT00639002
Drug: Dexamethasone 40 mg
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone was obtained commercially by Investigators in tablet strengths of 20 or 40 mg.
Study: NCT00298597
Drug: granulocyte - colony stimulating factor (G-CSF)
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00298597
Drug: erythropoetin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00967512
Drug: cenersen
Normalized name: Cenersen
DrugBank: Cenersen (DB15455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
Study: NCT00967512
Drug: idarubicin, cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: idarubicin, cytarabine
Study: NCT02866435
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In each clamp, a small intravenous catheter is placed in participant's arm for infusion of insulin together with potassium phosphate and glucose. Insulin is a hormone that body makes naturally and it causes blood sugar to decrease. Insulin (and glucose) will be infused in calculated doses to maintain blood sugar level in the target range of 95 mg/dl or 50 mg/dl depending on the clamp.
Study: NCT02866435
Drug: Glucose
Normalized name: Glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose is administered together with insulin and potassium phosphate during each clamp via the intravenous catheter. Glucose is a sugar and it is used to carefully regulate blood sugar level.
Study: NCT02866435
Drug: Potassium phosphate
Normalized name: Potassium phosphate
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Potassium phosphate is administered together with glucose and insulin during each clamp via the intravenous catheter. Potassium is a salt-like substance that is present in the blood.
Study: NCT00066677
Drug: rhuMAB-VEGF
Normalized name: rhuMAb-VEGF
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00066677
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02237365
Drug: 81mg aspirin
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet of 81mg aspirin and 2 tablets of placebo (visually matched to 500mg aspirin) daily for 60 days
Study: NCT02237365
Drug: 1000mg aspirin
Normalized name: aspirin 1000 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg aspirin daily for 60 days
Study: NCT05514925
Drug: Bevacizumab Injection [Avastin]
Normalized name: bevacizumab Injection [Avastin]
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal injection of bevacizumab (1.25 mg, 0.05 ml) in the inferior temporal quadrant of the eye, 4 mm behind the limbus in phakic eyes, and 3.5 mm in pseudophakic eyes.
Study: NCT00565240
Drug: Marvelon
Normalized name: isopropyl alcohol
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral contraceptive
Study: NCT00565240
Drug: Nuvaring
Normalized name: NuvaRing
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: contraceptive vaginal ring
Study: NCT00565240
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aromatase Inhibitors
Study: NCT02052752
Drug: 3% Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
Study: NCT02052752
Drug: 3% Benzoyl Peroxide Placebo
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
Study: NCT02348593
Drug: JZP-110
Normalized name: JZP-386 free base
DrugBank: JZP-386 free base (DB17068)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00928304
Drug: Florbetaben (BAY94-9172)
Normalized name: florbetaben
DrugBank: Florbetaben F-18 (DB09148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 megabecquerels (MBq) as single IV injection of 2 to 10 mL
Study: NCT00149890
Drug: Basiliximab
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Basiliximab (10 mg) was supplied as a lyophilisate in vials with ampoules of sterile water for injection (5 mL) and had to be given of 10 mg (body weight \<35 kg) or 20 mg (body weight ≥35 kg) strength.
Study: NCT00893061
Drug: anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00893061
Drug: exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00893061
Drug: letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00893061
Drug: tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT01125761
Drug: dexamethasone 0.5 mg and 1.0 mg clemastine cream
DrugBank: Clemastine (DB00283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
Study: NCT01125761
Drug: Dexamethasone 0,5 mg cream
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
Study: NCT04705922
Drug: TT-00420 Capsule
Normalized name: TT 173
DrugBank: TT 173 (DB17717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TT-00420 capsule formulation, administered orally
Study: NCT04705922
Drug: TT-00420 Tablet
Normalized name: TT 173
DrugBank: TT 173 (DB17717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TT-00420 tablet formulation, administered orally
Study: NCT00212056
Drug: ANP(hANP)
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0∙025 μg/kg per min for 3 days(intravenous)
Study: NCT00212056
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: placebo
Study: NCT02033434
Drug: Intranasal Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomized Intranasal Ketamine, 50mg
Study: NCT00149890
Drug: Cyclosporine/cyclosporine microemulsion
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine/cyclosporine microemulsion had to be started with 100 mg/m²/day intravenous (i.v) (2x4h) for 7 days and was to be continued i.v. or orally from day 8 onwards as per center practice. During the 6 months treatment period Cyclosporine doses had to be adjusted according to Cyclosporine A (CsA)-trough levels.
Study: NCT00938197
Drug: Fimasartan
Normalized name: Fimasartan
DrugBank: Fimasartan (DB09279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan (1d\~7d) Amlodipine (12d\~14d) Fimasartan + Amlodipine(15d\~21d)
Study: NCT00938197
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine (1d\~10d) Amlodipine (25d\~27d) Fimasartan + Amlodipine(28d\~34d)
Study: NCT04341311
Drug: Marizomib
Normalized name: Marizomib
DrugBank: Marizomib (DB11762)
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Intravenously initially given every other week over a 28 day course but will go to weekly x 3 and weekly x 4 as the dose levels increase Up to 26 courses.
Study: NCT04341311
Drug: Panobinostat
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: - Panobinostat: Oral dosage is given 3 times weekly, every other week over a 28 day course
Study: NCT00853866
Drug: reboxetine
Normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of 4mg reboxetine 80 minutes before assessment of Jebsen Taylor test
Study: NCT01748097
Drug: sodium bicarbonate 4.2%
Normalized name: Sodium Bicarbonate 4.2% Intravenous Solution
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04652076
Drug: NP137
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant humanized IgG1 monoclonal antibody against Netrin 1. NP137 will be administred IV, Q3W until disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, pregnancy or SMPC guidance, whichever occurs first.
Study: NCT04652076
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Humanised monoclonal anti-programmed cell death-1 (PD-1) antibody will be administred in IV Q3W. A maximum 35 cycles of treatments (approximately 2 years) with pembrolizumab can be administered to patients.
Study: NCT04652076
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.
Study: NCT04652076
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.
Study: NCT00391755
Drug: ramelteon
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. ramelteon 8mg po qhs with sleep and headache diary~2. placebo 1 po qhs with sleep and headache diary
Study: NCT01152190
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally, once daily for 8 weeks
Study: NCT00834834
Drug: Citalopram
Normalized name: Citalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose set by study psychiatrist, up to 60 mg daily. Treatment will last 6 months.
Study: NCT00687388
Drug: selective alpha 1-blockers
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued medication that the patient had before the enrollment of this study (tamsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks)
Study: NCT00191334
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250 mg/m2, intravenous (IV) day 1 and day 8, every 21 days x 6 cycles or disease progression or unacceptable toxicity
Study: NCT00191334
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2, intravenous (IV), every 21 days x 6 cycles or disease progression or unacceptable toxicity
Study: NCT02173106
Drug: steroid & Cyclosporin
DrugBank: Cyclo(his-pro) (DB02414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral methylprednisolone 0.4mg/kg/d and Cyclosporin for 6 months
Study: NCT03140657
Drug: Nanocurcumin
DrugBank: Cumin (DB10864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina). Subjects randomized to Nanocurcumin Arm will receive 80 mg/day for 4 months
Study: NCT00132119
Drug: nalmefene HCl
Normalized name: nalmefene HCl
DrugBank: Nalmefene (DB06230)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nalmefene HCl film-coated tablets, 20 or 40 mg, administered orally once daily for 10 weeks.